Cargando…
Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
MicroRNA (miRNA) and fibroblast growth factor receptor 1 (FGFR1) dysregulation are considered to play an important role in tumor proliferation, invasion, and metastasis. However, the regulatory mechanism between miRNAs and FGFR1 in lung cancer remains unclear and extremely critical. miR-214-3p was s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731303/ https://www.ncbi.nlm.nih.gov/pubmed/31492847 http://dx.doi.org/10.1038/s41389-019-0151-1 |
_version_ | 1783449663441993728 |
---|---|
author | Yang, Ying Li, Ziming Yuan, Hong Ji, Wenxiang Wang, Kaixuan Lu, Tingting Yu, Yongfeng Zeng, Qingyu Li, Fan Xia, Weiliang Lu, Shun |
author_facet | Yang, Ying Li, Ziming Yuan, Hong Ji, Wenxiang Wang, Kaixuan Lu, Tingting Yu, Yongfeng Zeng, Qingyu Li, Fan Xia, Weiliang Lu, Shun |
author_sort | Yang, Ying |
collection | PubMed |
description | MicroRNA (miRNA) and fibroblast growth factor receptor 1 (FGFR1) dysregulation are considered to play an important role in tumor proliferation, invasion, and metastasis. However, the regulatory mechanism between miRNAs and FGFR1 in lung cancer remains unclear and extremely critical. miR-214-3p was sharply decreased and showed a significantly negative correlation with FGFR1 in lung cancer patients (n = 30). Luciferase reporter assay confirmed that miR-214-3p could downregulate FGFR1 by directly targeting 3′-untranslated region (UTR). miR-214-3p inhibited the processes of epithelial–mesenchymal transition and Wnt/MAPK/AKT (Wnt/mitogen-activated protein kinase/AKT) signaling pathway by targeting FGFR1. Moreover, miR-214-3p not only established a negative feedback regulation loop with FGFR1 through ERK (extracellular signal-regulated kinase) but also developed a synergism with FGFR1 inhibitor AZD4547. In conclusion, our study demonstrated the regulatory mechanism between miR-214-3p and FGFR1 in lung cancer. miR-214-3p acts as a vital target in FGFR1-amplified lung cancer by forming a miR-214-3p-FGFR1-Wnt/MAPK/AKT signaling pathway network. Co-targeting miR-214-3p and FGFR1 could provide greater benefits to patients with FGFR1-amplified lung cancer. |
format | Online Article Text |
id | pubmed-6731303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67313032019-09-09 Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer Yang, Ying Li, Ziming Yuan, Hong Ji, Wenxiang Wang, Kaixuan Lu, Tingting Yu, Yongfeng Zeng, Qingyu Li, Fan Xia, Weiliang Lu, Shun Oncogenesis Article MicroRNA (miRNA) and fibroblast growth factor receptor 1 (FGFR1) dysregulation are considered to play an important role in tumor proliferation, invasion, and metastasis. However, the regulatory mechanism between miRNAs and FGFR1 in lung cancer remains unclear and extremely critical. miR-214-3p was sharply decreased and showed a significantly negative correlation with FGFR1 in lung cancer patients (n = 30). Luciferase reporter assay confirmed that miR-214-3p could downregulate FGFR1 by directly targeting 3′-untranslated region (UTR). miR-214-3p inhibited the processes of epithelial–mesenchymal transition and Wnt/MAPK/AKT (Wnt/mitogen-activated protein kinase/AKT) signaling pathway by targeting FGFR1. Moreover, miR-214-3p not only established a negative feedback regulation loop with FGFR1 through ERK (extracellular signal-regulated kinase) but also developed a synergism with FGFR1 inhibitor AZD4547. In conclusion, our study demonstrated the regulatory mechanism between miR-214-3p and FGFR1 in lung cancer. miR-214-3p acts as a vital target in FGFR1-amplified lung cancer by forming a miR-214-3p-FGFR1-Wnt/MAPK/AKT signaling pathway network. Co-targeting miR-214-3p and FGFR1 could provide greater benefits to patients with FGFR1-amplified lung cancer. Nature Publishing Group UK 2019-09-06 /pmc/articles/PMC6731303/ /pubmed/31492847 http://dx.doi.org/10.1038/s41389-019-0151-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Yang, Ying Li, Ziming Yuan, Hong Ji, Wenxiang Wang, Kaixuan Lu, Tingting Yu, Yongfeng Zeng, Qingyu Li, Fan Xia, Weiliang Lu, Shun Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer |
title | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer |
title_full | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer |
title_fullStr | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer |
title_full_unstemmed | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer |
title_short | Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer |
title_sort | reciprocal regulatory mechanism between mir-214-3p and fgfr1 in fgfr1-amplified lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731303/ https://www.ncbi.nlm.nih.gov/pubmed/31492847 http://dx.doi.org/10.1038/s41389-019-0151-1 |
work_keys_str_mv | AT yangying reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT liziming reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT yuanhong reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT jiwenxiang reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT wangkaixuan reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT lutingting reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT yuyongfeng reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT zengqingyu reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT lifan reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT xiaweiliang reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer AT lushun reciprocalregulatorymechanismbetweenmir2143pandfgfr1infgfr1amplifiedlungcancer |